An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective studyReport as inadecuate




An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study - Download this document for free, or read online. Document in PDF available to download.

BMC Gastroenterology

, 7:17

First Online: 31 May 2007Received: 09 January 2007Accepted: 31 May 2007

Abstract

BackgroundThe role of leptin in the course of liver disease due to chronic viral hepatitis CVH remains controversial. Our aims were to investigate the relationship between serum leptin concentrations and the severity of liver disease in a cohort of subjects with HBeAg negative chronic hepatitis B CHB and C CHC and to analyze the effect of body composition, the leptin system and insulin resistance together with viral factors on virologic response to antiviral treatment.

MethodsWe studied 50 36 men consecutive patients suffering from biopsy-proven CVH due to HBV n = 25 or HCV n = 25 infection. Thirty-two 17 men healthy volunteers served as controls. Levels of serum leptin and insulin were determined by immunoassays at baseline and at the end of the treatment.

ResultsA significant association between serum leptin levels and the stage of hepatic fibrosis was noted; patients with cirrhosis presented higher serum leptin levels compared to those with lower fibrosis stage CHB patients 17436 pg-ml vs 6028.5 pg-ml, p = 0.03, CHC patients 18014 pg-ml vs 4385 pg-ml, p = 0.05. An inverse correlation between lower leptin levels and response to lamivudine monotherapy was noted in patients with CHB; those with a virologic response presented lower serum leptin levels 5334 vs 13111.5 pg-ml; p-value = 0.003 than non-responders. In genotype 1 CHC patients, insulin resistance played a significant role in the response to antiviral therapy.

ConclusionOur data clearly suggest that cirrhosis due to CHB or CHC is associated with higher leptin levels. Increased serum leptin levels represent a negative prognostic factor for response to lamivudine monotherapy in patients with CHB. In CHC patients insulin resistance strongly influences the response to antiviral treatment in patients infected with genotype 1.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-230X-7-17 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Spilios Manolakopoulos - Sotirios Bethanis - Charis Liapi - Fotini Stripeli - Pantelis Sklavos - Alexandra Margeli - Aggelik

Source: https://link.springer.com/







Related documents